Inclusion Criteria:  Age ≥ 18 years old; Histologically confirmed HCC or meet the clinical diagnostic criteria of HCC; Unresectable HCC; The doctor decided to use donafenib before the patient was enrolled in the study； Informed consent and willing to complete the study according to the protocol.  Exclusion Criteria:  Those who are participating in clinical trials of other antitumor drugs; Allergic to any component of Donafenib tablets; Patients with active bleeding, active peptic ulcer, drug uncontrollable hypertension or severe liver dysfunction; Pregnant or lactating women.